Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Africa approved two GMOs in 2010

South Africa approved two Monsanto genetically modified crops for commercial cultivation in 2010, the International Service for the Acquisition of Agri-biotech Applications (ISAAA) reports. They were its insect-resistant YieldGard VT Pro (MON89304) and its glyphosate-tolerant and insect-resistant Genuity VT Double Pro (MON89034xNK603) maize. The former is only available for use with other events. The country also gave the green light to trials of five single event and seven stacked-trait maize lines, one single and five stacked-trait cotton lines, a disease-resistant grapevine, as well as four output traits for sugar cane, one for sorghum and another for cassava. Economic benefits from the adoption of GM crops amounted to $676 million in 1998-2009, the ISAAA reports. The GM crop area rose for the 13th consecutive year in 2010, with all cotton and three-quarters of maize planted with GM lines ( Agrow No 611, p 28).

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG004977

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel